Atopic Dermatitis (AD)

Atypical Dyschromia in Skin of Color
214822148221482DyschromiaABSTRACT Dyschromia is a concern for many patients, especially persons of color. Postinflammatory hypopigmentation and depigmentation can affect all skin types; however, it is more apparent in those with darker skin. Some members of the dermatology community may not comprehensively understand the mechanisms of these reactions and the extent of the psychosocial effect they have on persons of color …
Dyschromia
Omalizumab Therapeutic Cheat Sheet
168861688616886OmalizumabChronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Omalizumab
Skincare Mondays | Improving Quality of Life for Eczema Patients
168711687116871eczemaAtopic dermatitis (AD) is a chronic skin condition characterized by pruritus, inflammation, and acute flare-ups of eczematous lesions over dry skin.1 The wide range of clinical manifestations, the visible nature of the disease, and the intense itching significantly affects patients’ quality of life.2  Up to 80% of children with AD experience sleep disturbances.3 Sixty-seven percent of children …
eczema
Atopic Dermatitis (AD) Treatment Initiation and Monitoring
166031660316603atopic dermatitis (AD)During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
atopic dermatitis (AD)